27 October 2020 - - US-based needle-free injection technology developer PharmaJet's Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial, the company said.

The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding from the UK government to move forward with a clinical trial. Preparations for the clinical trial are well underway and the trial will begin as soon as possible.

The PharmaJet System was chosen due to its record of increasing the efficacy of nucleic acid-based vaccines and therapeutics.

DIOSynVax's innovative approach uses computer modeling of the virus's structure to identify the distinct genetic code.

The combined artificial intelligence and synthetic biology approach allows for development of a vaccine that is specific to developing antibodies against the SARS-CoV-2 virus.

PharmaJet's mission is worldwide acceptance of PharmaJet Needle-free Injection Systems as a standard of care in the vaccine delivery market.

The PharmaJet Needle-free Systems are safe, fast and easy-to-use.

They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.

The Stratis System has US FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.

The Tropis System has CE Mark and WHO PQS certification for intradermal injections.

DIOSynVax is a spin-out company from the University of Cambridge, set up in 2017 with the support of Cambridge Enterprise, the University's commercialization arm.

Their DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) technology will significantly accelerate vaccine antigen development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral haemorrhagic fevers.